Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Urinary Bladder Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Medulloblastoma 1Lung Neoplasms 1Leukemia, Hairy Cell 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 9Cyclophosphamide 7X-Rays 6Temozolomide 6Specimen Handling 6Phantoms, Imaging 6Biopsy 6Nuclear Medicine Department, Hospital 5Etoposide 5Nivolumab 4Bevacizumab 4Radiation 3Irinotecan 3Automobiles 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2lutetium Lu 177 dotatate 2larotrectinib 2ivosidenib 2etoposide phosphate 2erdafitinib 2ensartinib 2abemaciclib 2Watchful Waiting 2Radiotherapy 2ONC206 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × Histamine Antagonists × 1 year × Clear all
NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡